Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy

Adele D'Amico; Michela Catteruccia; Fabrizio De Benedetti; Marina Vivarelli; Manuela Colucci; Simona Cascioli; Enrico Bertini

doi:10.1016/j.ejpn.2011.08.002

Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy

Adele D'Amico, Michela Catteruccia, Fabrizio De Benedetti, Marina Vivarelli, Manuela Colucci, Simona Cascioli, Enrico Bertini

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article › peer-review

Abstract

Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.

Original language	English
Pages (from-to)	301-303
Number of pages	3
Journal	European Journal of Paediatric Neurology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/j.ejpn.2011.08.002
Publication status	Published - May 2012

Keywords

CIPD
Polineuropathy
Rituximab

ASJC Scopus subject areas

Clinical Neurology
Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/j.ejpn.2011.08.002

Cite this

Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. / D'Amico, Adele ; Catteruccia, Michela ; De Benedetti, Fabrizio ; Vivarelli, Marina ; Colucci, Manuela ; Cascioli, Simona ; Bertini, Enrico.

In: European Journal of Paediatric Neurology, Vol. 16, No. 3, 05.2012, p. 301-303.

Research output: Contribution to journal › Article › peer-review

@article{6036312427cd41148641dd0be4c5c565,

title = "Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy",

abstract = "Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.",

keywords = "CIPD, Polineuropathy, Rituximab",

author = "Adele D'Amico and Michela Catteruccia and {De Benedetti}, Fabrizio and Marina Vivarelli and Manuela Colucci and Simona Cascioli and Enrico Bertini",

year = "2012",

month = may,

doi = "10.1016/j.ejpn.2011.08.002",

language = "English",

volume = "16",

pages = "301--303",

journal = "European Journal of Paediatric Neurology",

issn = "1090-3798",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy

AU - D'Amico, Adele

AU - Catteruccia, Michela

AU - De Benedetti, Fabrizio

AU - Vivarelli, Marina

AU - Colucci, Manuela

AU - Cascioli, Simona

AU - Bertini, Enrico

PY - 2012/5

Y1 - 2012/5

N2 - Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.

AB - Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.

KW - CIPD

KW - Polineuropathy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84859949313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859949313&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2011.08.002

DO - 10.1016/j.ejpn.2011.08.002

M3 - Article

C2 - 21903431

AN - SCOPUS:84859949313

VL - 16

SP - 301

EP - 303

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 3

ER -

Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this